[Role of metabolites in the relationship between pharmacokinetics and the effect of beta blockers. Studies on tolamolol and bufuralol]
- PMID: 26114
[Role of metabolites in the relationship between pharmacokinetics and the effect of beta blockers. Studies on tolamolol and bufuralol]
Abstract
Plasma concentrations of tolamolol and bufuralol (beta-blocking agents) were measured after oral and intravenous administration to healthy volunteers. The plasma levels of their main metabolite was also determined. Simultaneously, the effect of the drugs on the heart rate and blood pressure was monitored under various stimuli (isoproterenol, exercise or orthostatism) and Valsalva maneuver. When given orally, the two drugs are extensively metabolized by a hepatic first-pass effect. After reaching the systemic circulation, they are metabolized in the liver to hydroxylated derivatives with similar pharmacologic activity as the parent molecule. For tolamolol it is possible to demonstrate a good correlation between parent drug blood levels and the pharmacodynamic effect; this relation is less evident for bufuralol. The pharmacokinetic analysis of the behaviour of the two beta-blocking agents and their main metabolite makes it possible to explain this difference in part. The results of the present study emphasize the importance of measuring metabolites when dose-action relationships are investigated.
Similar articles
-
[Pharmacokinetics of two beta blocking drugs: detection of a pharmacogenetic abnormality].Schweiz Med Wochenschr. 1976 Oct 9;106(41):1403-7. Schweiz Med Wochenschr. 1976. PMID: 12563 Clinical Trial. French.
-
Consequences of renal insufficiency on the hepatic clearance of some drugs.Int J Clin Pharmacol Res. 1983;3(6):459-74. Int J Clin Pharmacol Res. 1983. PMID: 6147317 Review.
-
[Effects of tolamolol and bufuralol on the arterial blood pressure and plasma renin activity. Contribution to the study of beta-blocking agents action mechanisms (author's transl)].Schweiz Rundsch Med Prax. 1978 Jan 3;67(1):27-35. Schweiz Rundsch Med Prax. 1978. PMID: 23523 French. No abstract available.
-
[Clearance concept applied to pharmacokinetics: 2. Experience with tolamolol (beta-blocking agent) in renal insufficiency (author's transl)].Nephrologie. 1980;1(4):177-82. Nephrologie. 1980. PMID: 6895408 French.
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
Cited by
-
Influence of renal failure on the hepatic clearance of bufuralol in man.J Pharmacokinet Biopharm. 1980 Oct;8(5):421-38. doi: 10.1007/BF01059544. J Pharmacokinet Biopharm. 1980. PMID: 6114166
-
Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers.Br J Clin Pharmacol. 1982 May;13(5):750-2. doi: 10.1111/j.1365-2125.1982.tb01453.x. Br J Clin Pharmacol. 1982. PMID: 6123344 Free PMC article. No abstract available.
-
The genetic control of bufuralol metabolism in man.Eur J Drug Metab Pharmacokinet. 1982 Jan-Mar;7(1):73-7. doi: 10.1007/BF03189547. Eur J Drug Metab Pharmacokinet. 1982. PMID: 6121708
-
Pharmacodynamic and pharmacokinetic studies on bufuralol in man.Br J Clin Pharmacol. 1986 Nov;22(5):527-34. doi: 10.1111/j.1365-2125.1986.tb02931.x. Br J Clin Pharmacol. 1986. PMID: 2878678 Free PMC article. Clinical Trial.